Explore Stanford technologies available for licensing:

Stanford inventors have developed a nanoparticle containing the toll-like receptor agonist (TLR7-NP) that elicits a potent anti-tumor immune response in multiple cancer types without inducing undesired systemic inflammation and toxicity.

Stanford researchers have invented a novel nanobody-based platform for specific activation of bone and cartilage regeneration.

Based on their proprietary HyTEC tissue engineering platform, researchers at Stanford have developed an osteoinductive intramedullary implant (IM) device for improved bone healing.

Researchers at Stanford have developed a porous biologics-loaded multimaterial construct, called Hybrid Tissue Engineering Construct (HyTEC), with applications in regenerative medicine and therapeutic delivery.

Technology Reference
CZB-213S
Stanford ref. no. S21-152

Researchers at CZ Biohub SF and Stanford have developed unique fusion proteins that have broad therapeutic benefits for the treatment of infection by existing and future coronaviruses.

Stanford researchers have found that aging and disease lead to skeletal stem cell (SSC) dysfunction and hence decreased bone health.

Targeted protein degradation is an emerging strategy for the elimination of classically undruggable proteins. Mucins are known to be involved in tumor-progressive pathways but are difficult to target using small molecules and antibodies.

Colorectal cancer affects 1.4 million new patients annually, with existing treatments often ineffective. A key factor in treatment resistance is high aldehyde dehydrogenase activity, which undermines several chemotherapies.

Cancers including breast, lung, colon and prostate account for almost ten million deaths worldwide every year. The main cause of cancer deaths is metastasis, which is the propensity of cancer cells to spread throughout the body.

Antimicrobial peptoids are promising leads for novel antibiotics; however, their activity is often compromised under physiological conditions. Inventors at Stanford enhanced the efficacy of antimicrobial peptoids by using thiourea and thiourea derivatives.

Drs.

Stanford researchers led by Dr.

Stanford researchers in the Snyder lab have discovered and developed an innovative immunoglobulin modality for the treatment of insulin resistance and type 2 diabetes.

Stanford scientists have discovered a new immunotherapeutic target for treating lung cancer and fibrotic lung disease.

Activation of hedgehog signaling pathway can facilitate stem cell proliferation and holds great promise in regenerative medicine for a variety of indications.